In a new report, analysts at Clarivate, a London-based intelligence and research firm, identified seven experimental treatments in late-stage development that they expect to deliver annual sales of more $1 billion within five years.
They include treatments for common conditions such as Alzheimer’s disease and asthma to those for very rare diseases such as transthyretin amyloidosis, which is characterized by a build-up of deposits of amyloid, a protein, in various organs.Transthyretin amyloidosis is less common among Americans of European descent, where it is estimated to affect one in 100,000 people, but cardiac form affects between 3% and 3.9% of African Americans.
Here are the seven treatments that are likely to achieve blockbuster status in the next five years according to Clarivate:
- Adagrasib (Mirati Therapeutics Inc and Zai Lab Limited). The “long-awaited, targeted treatment” will likely be the first such treatment option in patients with colorectal cancerwith the KRASG12C mutation, who historically have had very few treatment options. Clarivate said in a news release.
- Faricimab (Roche and Chugai Pharmaceutical). For patients with diabetic macular edema (DME) or wet age-related macular degeneration (AMD), faricimab offers a potentially more convenient option as it will be administered less frequently, on average, than the standard of care, Clarivate said in its news release. “As the first bispecific antibody to launch in ophthalmology, it also has the potential to be more efficacious than current standard of care, although data so far indicate it is non-inferior to the standard of care,” said the release
- Lecanemab (Eisai Co. Ltd. and Biogen)
- and donanemab (Eli Lilly) .“In this underserved market, anti-Aβ MAbs lecanemab and donanemab are poised to follow on the heels of the U.S. FDA’s landmark accelerated approval of Aduhelm for the treatment of AD,” Clarivate said. Lecanemab and donanemab could offer differentiated clinical profiles, which may be bolstered by phase 3 results that are expected to be reported beginning in late 2022. “Data across clinical trials suggest that sufficient exposure to optimal doses of anti-Aβ MAb therapy could be clinically effective in early AD,” Clarivate said.
- Tezepelumab(Amgen and AstraZeneca). The medication is a “potential game changer” for patients with non-TH2 or TH2-low asthma whose asthma is not well-controlled with inhaled corticosteroids, the current standard of care, according to Clarivate. “If approved, it would be a first-in-class biologic for this patient population. Tezepelumab will likely be a first-line biologic for severe TH2-low asthma and a treatment option for patients with TH2-high asthma for whom existing therapies have been less successful,” Clarivate said.
- Tirzepatide(Eli Lilly). The drug offers indication-leading reductions in weight loss and improvements in glycemic control in a growing patient population, which has the potential to reduce the incidence of complications from type 2 diabetes. “A new treatment that can more effectively address both weight loss and glycemic control than existing treatments would potentially be of great benefit to patient outcomes,” Clarivate said.
- Vutrisiran (Alnylam Pharmaceuticals). Not only does this drug enter a relatively underserved market overall, it also has more convenient dosing options than other transthyretin amyloidosis -specific drugs on the market, Clarivate said. “For a progressive disease with a lot of unmet need, this drug brings efficacy, a generally favorable safety profile, and improvements in delivery that will benefit patient quality of life,” said the Clarivate press release.